A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis
A study for patients with Idiopathic Pulmonary Fibrosis using study drug FG-3019
Sponsor: FibroGen
Enrolling: Male and Female Patients
IRB Number: AAAQ7503
U.S. Govt. ID: NCT01890265
Contact: Imaani Easthausen: (212) 342-4551 / ije2103@columbia.edu
Additional Study Information: This study is for subjects with Idiopathic Pulmonary Fibrosis (IPF). IPF is an uncommon long-term disease that causes scar tissue to build up in the lungs, damaging the lung tissue. Idiopathic means that there is no known cause. Subjects with IPF have symptoms such as cough, shortness of breath, and reduced ability to exercise. The purpose of this study is to find out if you can take the prescribed dose of FG-3019 without problems, and whether FG-3019 is safe and helps subjects with IPF. FG-3019 is called aninvestigational or experimental drug because it has not been approved for use in people by the Foodand Drug Administration (FDA), the branch of U.S. government which approves new drugs, or byany other regulatory agency in other countries.
This study is closed
David Lederer, MD
Do You Qualify?
Have you been diagnosed with Idiopathic Pulmonary Fibrosis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Imaani Easthausen
(212) 342-4551